In a true bubble, investors wouldn't be so quick to exit disappointing stocks. But they are choosing to separate the good from the bad. » Read More
Looking for better returns in a volatile rate marketplace? Experts suggest looking carefully at corporate junk bonds and dividend stocks.
The global economy requires a globally informed investor. Learn about anti-fraud efforts from other parts of the world.
Competing financial priorities, such as student loans and caring for aging parents, may take you off course when trying to fund retirement.
Energy stocks eventually will go up unless the global economy collapses. But keep it simple. Don't overthink your basis for a rebound bet.
Retirement guides run the gamut—from stating the obvious to engaging in scare tactics. Here's a checklist of things to boost your savings.
Affordability and credit are factors that could blow the steam out of any housing rebound. Young first-time buyers remain cash-strapped.
There are smart ways investors can diversify holdings in preparation for rising bond yields. Options include floating-rate and value funds.
Think you have what it takes to be a do-it-yourself investor? There are at least 7 essential traits you need to be successful.
Big companies are betting DIY investors want some help when constructing their portfolios—and are jumping into the $19 billion market.
It's time for investors to take an activist approach and search for hidden fees and conflicts of interest, Vanguard's founder says.
Take an in-depth look at the world of modern medicine - examining the treatments, companies and people making a difference in the way we treat illness and injuries today, and laying the foundation for the medical treatments of tomorrow.
THE PULSE is a look at technology’s impact on our daily lives and how it will affect us in the future.
The buzz on the trading floor
Positive earnings have Brad McMillan bullish on stocks for 2017, so he's not concerned about any short-term pullbacks.
Citron Research's Thursday tweet sent shares of Express Scripts tanking, and someone appeared ready for the move.
Earlier Thursday, Left's Citron Research called Express Scripts the "Philidor of the pharma industry."